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1. Introduction 
For more than 50 years, antibradycardia pacemakers have been implanted. Technological 
developments have led to an improvement, extension of diagnostic and treatment options 
(such as holter function for detecting arrhythmias and biosensors), and to an increasingly 
more automated device management (control of sensing and stimulus thresholds). 
Furthermore, it was possible to extend the runtime of the pacemaker assembly. 
In 1980, the first implantable cardioverter-defibrillator (ICD) has been implanted in a human 
being with the objective of secondary prevention of sudden cardiac death. Meanwhile, 
advances in technology have led to a size reduction of the device assembly and to the 
possibility of transvenous implantations. Due to the MADIT II-study, published in 2002, the 
ICD-implantation indications have broadened to include patients with coronary artery 
disease in the primary prevention of sudden cardiac death (A.J. Moss et al., 2002).  
Since the 1990´s, biventricular pacemakers and ICDs enabled with Cardiac 
Resynchronization Therapy (CRT) are being implanted in patients with reduced left 
ventricular ejection fraction, prolonged QRS-complex, and advanced heart failure. 
These patients undergoing CRT perceived improvement in heart failure symptoms (M.R. 
Bristow et al, 2004). Clinically asymptomatic patients with reduced left ventricular pump 
function and prolonged QRS-complexes are now also being considered candidates for 
implantation of biventricular pacemakers and ICDs to prevent cardiac decompensations (C. 
Linde et al., 2008; A. J. Moss et al. 2009). 
In recent years, national and international associations have drawn up guidelines for 
implantation of antibradycardia, ICD, and CRT devices (biventricular pacemakers and 
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ICDs) (A.E. Epstein et al., 2008). Recently, implantation rates for antibradycardia 
pacemakers, ICD and CRT devices have constantly increased. 
In the USA, the expansion of indications for ICD and CRT implantations to include primary 
prevention of sudden cardiac death led to an amplification of ICD and CRT implantations. 
Device therapy is increasingly used even in elderly multimorbid patients. While the number 
of pacemaker aggregate replacements remained constant in 1992-2006, the number of ICD 
aggregate replacements decreased during this period, due to runtime extension of ICD 
aggregates (C. Zhan et al., 2007, S.M. Kurtz et al, 2010). 
However, despite technical improvements in implantation and devices complications are to 
be expected. Alter et al. studied 440 ICD patients with a median follow-up of 46 (+/ - 36) 
months and found a complication rate of 31%. This primarily involved peripoerative 
complications (10%), inadequate shock outputs (12%), ICD-lead related complications (12%) 
and complications caused by the aggregate (6%) (P.  Alter  et al., 2005).  
Pacemaker and ICD annual reports submitted to the FDA revealed high annual malfunction 
replacement rates for pacemakers (1.4 – 9.0 replacements per 1000 implants) and for ICD´s 
(7.9 – 38.6 replacements per 1000 implants). The annual pacemaker malfunction replacement 
rate per 1000 implants decreased significantly during the study period 1990-2002. In 
contrast, the ICD malfunction replacement rate per 1000 implants increased markedly 
during the same period. In recent years, the problems surrounding the sprint fidelis lead 
showed the risk of lead and aggregate failures (M. Maytin et al., 2010). Defects of ICD-leads 
may even occur after implantation. Data presented by Kleemann and his colleagues who 
reported on survival of transvenous defibrillation leads during long-term follow-up 
revealed that the annual failure rate increased progressively with time after implantation 
and reached 20% in 10-year-old leads (T. Kleemann et al., 2007) 
 
- increasing rates of implantation (especially for ICD- and CRT-systems) 
- growing number of patients with implanted pacemakers, ICD-, and CRT-systems 
 (follow-up appointments, aggregate replacement) 
- growing number of elderly patients with comorbid conditions 
- new diagnostic options (arrythmia management, biosensor technology) 
- trend towards automated aftercare (e.g. automatic stimulus treshold determination) 
- risk of device-related malfunctions (e.g. lead defects) 
- fast transitions to new models in complex ICD- and CRT-systems 
Table 1. Trends and problems in device therapy 
The current developments and risks in device therapy (table 1) prescribe requirements to be 
met in terms of patient safety, follow-up appointments, and an increasingly complex 
management of ICD- and CRT-patients. 
A device-based remote-monitoring represent an important contribution to meet these 
requirements and fulfill the needs. 
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2. Principle and development of technology 
Remote monitoring overcomes the spatial separation between patient and physician. In the 
meantime, device-based remote monitoring has become a classical field for telemedical 
applications in cardiology, in addition to diagnostics of cardiac arrhythmia and 
telemonitoring of chronic heart failure (CHF)-patients. 
Already in the mid of the 1970s, first examinations of transtelephonic monitoring of patients 
with antibradycardia pacemakers were carried out. At first, ECGs were recorded and 
transmitted via telephone to a receiving centre. A transmission of pacemaker function was, 
however, not possible (C. H. Klingenmaier et al., 1973). Medtronic “CareLink 2090” and St. 
Jude Medical “Housecall”  were the first systems to allow remote monitoring. The CareLink-
System enabled the computer in the monitoring centre to connect via telephone to the 
device. Thus, remote monitoring bridged the spatial distance between two different 
observers and thus a consultation without any active intervention in programming became 
possible. 
St. Jude Medical developed the “Housecall” -System to transmit data from the ICD and the 
CRT-D to the physician. The system allows the patient to gather and transmit information 
to the practitioner about the ICD using the Housecall Plus Transmitter. The information 
provided by the IEGM and the online intracardiac ECG allows  realtime ICD-surveillance 
for the first time. Either the patient or the physician can initiate the call to transmit via the 
small transmitter up-to-the-second information about how the patient's heart and ICD are 
working. The system enables the physician to monitor device performance. A 
determination of stimulus thresholds and a programming of the ICD settings, however, 
were not possible yet. 
In the 1990s, BIOTRONIK started the development of the “Home Monitoring”-technology. 
First pacemakers were implanted in 2000. Today, hundreds of thousands of BIOTRONIK 
Home Monitoring systems have been implanted. The Home Monitoring System is the only 
remote monitoring system in which the transmission of data to the CardioMessenger 
requires no action by either the patient or the practitioner. The CardioMessenger transmits 
the data to BIOTRONIK's Service Center via a cell phone. The Service Center analyzes the 
data and forwards it to the patient's physician either by sms, email or fax. The Home 
Monitoring concept has been modified slightly and extended, and nowadays it represents 
the technological basic principle for telemonitoring for patients with electrical implants. All 
telemonitoring systems consist of the following components: Implanted device, patient 
monitor, the provider´s data server, data presentation for the physician (figure 1).  
In the meantime, almost all manufacturers (BIOTRONIK, Medtronic, St. Jude Medical, 
Boston Scientific) have developed their own concepts for remote monitoring of pacemakers, 
ICD´s and CRT-systems, which in spite of their uniform structure vary in their technical 
realization and features (table 2). 
Data can be transmitted from the implant to the patient monitor in various ways. This 
includes, for instance, transmissions that can be initiated automatically without any user 
interaction (Home Monitoring, BIOTRONIK) or by radio frequency (RF) wireless telemetry 
that is used to download data from the device (Merlin.net, St. Jude Medical; LATITUDE, 
Boston Scientific). In contrast, data can be transmitted manually by the patient (CareLink, 
Medtronic). Figure 2 shows patient monitors both for automated and manual data 
transmission. 
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Fig. 1. Individual components of a device-based remote monitoring for patients with 
pacemakers, ICD´s and CRT-systems 
System 
(manufacturer) 
Implants 
Patient monitor 
(data transfer 
from the 
implanted 
device) 
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Table 2. Overview of different systems for remote monitoring of pacemakers (PM), ICD´s 
and CRT-systems  
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Fig. 2. Various patient monitors for remote monitoring of implants (a: CardioMessenger, 
BIOTRONIK; b: CareLink-Monitor, Medtronic; c: Merlin@home, St. Jude Medical; d: 
LATITUDE Communicator, Boston Scientific) 
The patient monitor is the interface between the implant and the data servers. The data 
transmission from the patient monitor to the manufacturer´s data servers can be carried out 
via landline or mobile phone. Individual providers use both ways. The advantages of data 
transfer via mobile phone are the independence of location and the absence of a fixed 
telephone line. 
In future, however, the mobile phone technology is certainly going to be the dominant 
model. The provider´s data servers collect the data and present it to the physician. There is 
no active processing of the medical data. In addition, all transmitted data are saved in the 
servers according to the requirements with data security. 
The treating physician can receive the data via fax, sms or internet. In the meantime, all 
vendors have developed password protected internet platforms. This permits an access to 
patient data from any computer. Apart from data concerning system integrity (actual 
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programming of the aggregate, battery status, thresholds, impedances etc.) diagnostic data 
are also available (heart rate at rest and during exercise, atrial fibrillation etc.). The data 
transfer is carried out at scheduled times (e.g. once a day). Moreover, additional data 
transmissions can be carried out in case of ICD-Rx. Thus, due to the modern remote 
monitoring systems offered by the vendors complete datasets can be transmitted and 
presented. The manufacturers have therefore developed special user interfaces in order to 
allow an immediate data review. Furthermore, the physician can ask the patient via patient 
monitor to contact the physician by phone.  
The different systems for remote monitoring (Home Monitoring, BIOTRONIK; CareLink,  
Medtronic; Merlin.net,  St. Jude Medical; LATITUDE, Boston Scientific) are described in 
detail below. 
3. Different systems for remote monitoring  
3.1 Home Monitoring  
BIOTRONIK Home Monitoring System is the first wireless, mobile remote monitoring 
system for patients with implantable cardiac devices on the market today. All devices have 
an integrated antenna in the header, enabling an automatic and patient-independent remote 
and wireless telemetry to a transmitter device (CardioMessenger®, figure 2). Data 
transmission is initiated at times predetermined by the physician, normally during night-
time. Data transfer from the implant to the CardioMessenger® is provided via ULP-AMI 
(ultra low-power active medical implants) operating in the 402-405 MHz Band, which is 
worldwide standardized; its terms of use are laid down in relevant standards. In Europe, the 
standard ETSI EN 301 839-1 V1.2.1 (2007-07) is applied. The data are transmitted from the 
patient monitor via a mobile phone network to the BIOTRONIK Service Center. There, the 
data are put into an easily accessible form and can then be viewed by the physician online 
via the internet on a password protected website (Home Monitoring Platform®). 
BIOTRONIK Home Monitoring uses an intuitive, color-coded, web-based system (red and 
yellow) physicians and clinic staff, which allows for automatic patient classification aimed at 
significantly simplifying clinic workflow. In addition, the types of events which trigger an 
alert can be customized for each patient. The physician is informed by e-mail, sms, fax or 
phone messages whenever critical data or pre-defined, individual events are available for 
consultation. In addition to exporting data in CSV files, files can be exported using the 
Portable Document Format (PDF) standard. Data transfer is fully automated and requires no 
manual support by the patient. Furthermore, the system provides the opportunity to 
configure individual filter settings for data transfer according to individual patient needs 
and the desired level of safety. As an additional feature, IEGM Online HD®, a high-
definition intracardiac ECG, can also be transmitted for patients with implanted ICD and 
CRT-devices (figure 3).  
In addition, mathematical modeling enables the integration of different parameters (e.g. 
heart rate, right ventricular impedance, intrathoracic impedance measurement) into a 
complex monitoring concept (Heart Failure Monitor®). This unique system allows the 
attending physician to monitor each patient with dual-chamber pacemaker or CRT devices 
very closely and to react in time to prevent potential cardiovascular events at an early stage. 
Home Monitoring has, however, the disadvantage that only aggregates using an antenna 
integrated in the device can be monitored; external sensors (blood pressure monitor, weight 
scale etc.) cannot be integrated into the system. 
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Fig. 3. Intracardiac ECG (IEGM), transmitted via Home Monitoring: detection of a sustained 
ventricular tachycardia (above) – Termination after shock (below) 
3.2 CareLink  
Medtronic CareLink has evolved from the Remote-View-System. The patient can collect 
data by holding an antenna over his implanted device. The system is backward compatible, 
so that patients with older devices can also be monitored. The data are captured by the 
antenna, downloaded by the monitor (CareLink-Monitor®) and transferred to the 
Medtronic CareLink Network (figure 2). Through this network, patient data are transmitted 
from their implantable device using a portable monitor that has to be connected to a 
standard telephone line. The patient's physician can view the data on a secure internet 
website (figure 4). 
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Fig. 4. Password-protected internet platform of the CareLink-system (source: Medtronic) 
The network also allows Medtronic CareAlert® notifications to be transmitted when any of 
the programmable alert conditions from a patient’s implanted device has occurred. The data 
transfer performs via standard telephone line. The system can be used for remote 
monitoring of implantable event recorders (Medtronic Reveal®). CareLink allows to 
transmit information on system and diagnostic data (Cardiac Compass®) and IEGM´s 
(event-triggered and on demand). 
Another option for remote monitoring is OptiLink®, which incorporates CareLink and 
OptiVol®. The latter was developed to monitor patients with implanted CRT-D devices and 
to detect possible cardiac decompensations at early stage. The system measures the drop of 
intrathoracic impedance upon intrapulmonary fluid accumulation. Data are reliably 
transmitted via Medtronic's exclusive Conexus Wireless Telemetry®. This provides the 
physican with helpful tools to prevent cardiac decompensation. This may also lead to 
prevent hospitalizations for acute decompensated heart failure.  
3.3 Merlin.net 
St. Jude Medical Merlin.net is the successor to the Housecall Plus®-Remote Patient 
Monitoring. The monitor Merlin@home® is the core of the system (figure 2). Data are 
transmitted daily wirelessly (via RF) to the Merlin@home® Transmitter and from there via 
telephone to the internet-based Merlin.net server. Merlin@home supports all RF telemetry 
equipment (ICD, CRT-Ds).  
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The system also allows physicians to compile a more complete patient record, by easily 
transferring cardiac device data into electronic health records (EHRs), figure 5. Data transfer 
is compatible with IHE HL7 and IEEE 11073. 
 
 
Patient monitor
Merlin@home
Programming
unit
Patient with
implanted device
(ICD, CRT)
using RF-telemetry
Merlin.net
Server
(Data server)
Electronic Health
Records – EHR
Internet platform
Technical support (Hotline)
physician
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DirectAlerts via
E-mail, sms, fax
 
 
Fig. 5. Complex remote monitoring with St. Jude Medical Merlin.net – Integration of 
telemedical and direct aftercare (modified according to St. Jude Medical) 
Data gathered during outpatient aftercare can also be integrated into the system. 
Additionally, St. Jude Medical provides help service that both patients and physicians may 
call with any technical questions or problems they may be experiencing. Merlin.net features 
include DirectCall® message, which provides pre-recorded messages that clinics can 
program to call patients to remind them of upcoming scheduled follow-ups, inform them if 
they have missed a follow-up, confirm that their transmitted data has been reviewed or ask 
them to call their physician's office or the hospital for more information. The DirectAlerts® 
Notification feature can be used to alert a physician to changes in the device or the patient’s 
disease state. 
3.4 LATITUDE 
The Boston Scientific LATITUDE Patient Management system is being used mainly in the 
USA. It integrates remote monitoring of ICD- and CRT-systems (Remote Follow-up), 
telemonitoring, and heart failure management. Patients may initiate data transmission. 
LATITUDE Communicator® serves as the patient monitor (figure 2). The LATITUDE 
Communicator® uses RF to send and receive signals from the implanted device and a 
bluetooth communication system to communicate with an optional weight scale and blood 
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pressure monitor. The information is then transmitted via the phone line to a secure server.  
An Internet-based system provides easy access to diagnostic information from a patient's 
device and puts the physician in control of remote data collection. Design of the internet 
platform largely corresponds to that of the device.  
The internet platform provides several care providers secure access to patient data (figure 6). 
 
 
 
Fig. 6. LATITUDE-system (Boston Scientific) – Integration of external sensors (weight scale 
and blood pressure monitor) into the device-based remote monitoring (modified according 
to Boston Scientific) 
The advantage of the LATITUDE -system is the possibility to integrate external devices 
(weight scale and blood pressure monitor), which reflects a fundamental part in monitoring 
patients with CHF. 
4. Remote monitoring in clinical practice 
Since the 1990s, device-based Remote Monitoring is being used in clinical practice. Now 
almost all pacemaker and ICD manufacturers have developed and improved internet-based 
solutions. Due to evidence-based medicine scientific studies are being required to prove 
efficacy or effectiveness and efficiency of remote monitoring. 
Especially aspects concerning data security, advantages over conventional aftercare and cost 
efficiency have to be taken into consideration. 
Clinical studies on remote monitoring of patients with pacemakers, ICDs, and CRT-systems 
investigated technical feasibility and safety of data transfer, first. In these breaking studies 
focusing on patients with implanted pacemakers, stability and safety of transtelephonic data 
transmission could be proved. In a study of 93 patients, Wallbrück et al. assessed the 
feasibility of an automatic long-distance monitoring system (Home Monitoring®, 
BIOTRONIK) for pacemaker patients, and the clinical relevance of transmitted data. Three 
patients (3.2%) were excluded due to insufficient mobile net coverage at their living site. For 
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the other patients, 5311 of 5911 messages were successfully registered. Interrupts in the 
sequence of messages occurred 331 times. Two hundred ten of these (63%) lasted just 1 day, 
14 interrupts (4%) lasted 5 or more days. This rate could be reduced by providing 
information to the patients (K. Wallbrück et al., 2002). In a prospective study, 59 ICD-
patients were followed remotely using the CareLink-system; patient acceptance of the 
system was high; satisfaction by the medical staff with data quality was also very favourable 
(M. H. Schoenfeld et al., 2004).  The PREFER-study showed that the strategic use of remote 
pacemaker interrogation follow-up (CareLink, Medtronic) detects actionable events that are 
potentially important more quickly and more frequently than transtelephonic rhythm strip 
recordings (G.H. Crossley et al., 2009). 
Stability of data transfer can be optimized in various ways:  
The patient monitor can indicate disturbed data transmission through the flashing of its 
associated visual indicator. Another option is to use systems that remind patients to initiate 
data transmission (Merlin@net, St. Jude Medical). The Home Monitoring system enables the 
physician to define automatic and individually configurable notification if data transfer is 
missing. A service-hotline for patients can increase data transmission rate. 
The application of unified bandwidths allows secured data transfer. However, 
reprogramming of the implant via remote monitoring is not possible due to law restrictions. 
Device-based remote monitoring of patients with implanted antibradycardia pacemakers, 
ICDs and CRT-systems includes the four following aspects (figure 7): 
 
 
Fig. 7. Four relevant aspects of device-based remote monitoring in patients with implanted 
antibradycardia pacemakers, ICD, and CRT- systems 
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Device-management is an important tool used to monitor system integrity and to provide 
security of implants. 
Important parameters (battery charge condition, atrial and ventricular signals, ICD-status 
etc.) are transferred. 
Today, the complete actual device programming is transferred and visualized. This data 
primarily ensures patient security by enabling a complex device monitoring. In various 
cases, remote monitoring has been shown to confer clinical benefits. 
BIOTRONIK Home Monitoring enables physicians to detect severe lead problems (e.g. lead 
fracture, lead micro dislocations, Twiddler-syndrome) early and to react quickly (N. J. 
Varma, 2008; M. L. Loricchio et al., 2008; M. F. Scholten et al., 2004).  Intracardiac ECG serves 
as an important tool used to detect device malfunctions. Patient safety may be increased due 
to remote monitoring. This particularly concerns patients with highly complex devices 
(ICDs and CRT-systems). Nevertheless, the overall prevalence of technical problems was 
rather low. Nielsen et al. monitored a total of 260 patients with Home Monitoring ICDs. 
Technical events for single and double chamber ICDs occured only in 0.8% of patients and 
included invalid shock coil impedance, invalid ventricular lead impedance and special 
implant status (J. C. Nielsen et al., 2008). The retrospective study by Lazarus, which reported 
on the results of 11,624 patients implanted with a pacemaker, an ICD or a CRT-system using 
the BIOTRONIK Home Monitoring, revealed similar findings. Most transmitted events had 
medical reasons (e.g. cardiac arrhythmia) (A. Lazarus, 2007). 
Arrhythmia management is an important partial aspect of device-based Remote Monitoring. 
It allows to detect mean patient heart rate at rest and at a workload performance and 
occurrences of atrial and ventricular arrhythmias. Ahmadi-Kashani et al. could show in their 
INTRINSIC RV study that an elevated heart rate in patients with a dual-chamber ICD is 
significantly associated with greater risk of achieving the primary end point of death or 
heart failure hospitalization. Of patients with a mean HR < 75 bpm, 5.8% died or were 
hospitalized for heart failure, whereas 20.9% with a mean HR > 90 bpm achieved the same 
end point, a 3.6-fold difference (M. Ahmadi-Kashani et al., 2009). In addition, early detection 
of atrial defibrillation is an important aspect in rhythm monitoring. Paroxysmal atrial 
tachycardias are often asymptomatic. In the presence of atrial fibrillation, thromboembolic 
events and progression of CHF may further deteriorate the patient's prognosis. During the 
CHAMP-study, 25 out of 120 patients with CRTs experienced paroxysmal atrial 
tachycardias, for an incidence rate of 21%. Paroxysmal atrial tachycardias were recorded in 
29 and 17% of patients with and without previous history of atrial fibrillation, respectively 
(C. Leclercq et al, 2010).  Remote monitoring allows early detection of atrial fibrillation in 
patients with implanted pacemakers, ICDs and CRT-systems and early reaction to optimize 
medical treatment (antiarrhythmic drug therapy, anticoagulation) (N. Varma et al., 2005; R. 
P. Ricci et al., 2009 a). Compared to scheduled follow-ups (usually every 3-6 months), 
remote control and, thus, an early detection of paroxysmal atrial tachycardias may lead to a 
reduction of stroke (R. P. Ricci et al., 2009 b).  
Among patients, in whom an ICD is implanted, shocks, appropriate or inappropriate, 
always represent a major problem as they are associated with a poor prognosis. (M.O. 
Sweeney et al., 2010). Furthermore, mental and emotional health seems to fall with repeated 
ICD shocks. Progressive heart failure was the most common cause of death in patients who 
received a shock (J. E. Poole et al., 2008). Inappropriate shocks are often related to technical 
failure in device sensing (lead malfunction, T-wave-oversensing) or to cardiac arrhythmia. 
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These inappropriate shocks can be reduced through remote monitoring which is helpful for 
early detection of technical and medical events as well as by new algorithms to preven 
shocks (K.J. Volosin et al., 2010).  In addition, intracardiac electrogram is also helpful (J.C.J. 
Res und Mitarbeiter, 2006; S. Spenker et al., 2009).  
In recent years, heart failure management of patients with ICDs and particularly of those 
with CRT-systems, is attracting interest in clinical scientific studies. There are many complex 
reasons for that: New methods focussing on biosensors (e.g. intrathoracic impedance 
measurement) allow better monitoring of potential cardiac decompensations. Another 
reason is that patients often need residential treatment due to heart failure.  
The latter increases costs and also results in a negatively effect quality of life.  
Therefore, manufacturers have developed various concepts (e.g. Medtronic Cardiac 
Compass®, BIOTRONIK Heart Failure Monitor®). The aim of these concepts is to enable an 
“early warning system” to impeding episodes of worsening heart failure through 
integration of various components (e.g. heart rate at rest and in the recovery phase, patient´ s 
physical activity, arrhythmia load, intrathoracic impedance). These concepts are currently 
under investigation in prospective studies. Despite promising approaches in intrathoracic 
impedance measurement (Optivol®, Medtronic), the method remains problematic due to 
limited sensitivity, specificity, and positive predictive value (D. Vollmann et al., 2007; D. 
Cantazariti et al., 2009). Other remote monitoring concepts (LATITUDE, Boston Scientific) 
are able to integrate external sensors (weight scale, blood pressure monitor via bluetooth). 
Thus, monitoring of ICD- and CRT-patients with CHF presents a complex problem. 
Therefore, device-based remote monitoring offers many possibilities and chances. 
Experiences already exist for Medtronic CareLink and for BIOTRONIK Home Monitoring. 
Tachyarrhythmia and cardiac decompensation events in patients with an implanted CRT 
could be treated efficiently due to CareLink. Patients benefited from an early therapeutic 
interventions (M. Sanitini et al., 2009). 
 In their “Home CARE” pilot study conducted in 123 patients with clinical indication for 
CRT Ellery et al. examined Home Monitoring in cardiac resynchronization therapy. In 70% 
of the rehospitalization events, the retrospective analysis of transmitted data via Home 
Monitoring revealed an increase in mean heart rate at rest and in mean heart rate over 24 h 
within 7 days preceding hospitalization. Both duration of physical activity and the rate of 
biventricular stimulation were reduced. Home Monitoring of these data may predict events 
leading to hospitalization (S. Ellery et al., 2006). Different studies concerning device-based 
remote monitoring of patients with CHF are currently being carried out (e.g. InContact-
Studie, St. Jude Medical). 
Patient-centered management forms a fourth aspect that has to be mentioned in this context. 
The concept for the monitoring and treatment of CHF is extended by various measures 
(telephone calls, drug adherence monitoring, patient training). Integration of special 
telemedical service centres enables comprehensive patient care with the centre taking the 
role of coordinator within the network consisting of GP, resident cardiologist and hospital. 
The aim is to implement medical treatment in accordance with the guidelines in order to 
improve the patients´ quality of life, to prevent hospitalizations and to improve patients´ 
prognosis. New information processing technologies allow the integration of collected data 
into an electronic health record (EHR) with password protection which can be accessed by 
individual physicians (GP, resident cardiologist and physicians at hospital). 
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The numbers of follow-up will increase with the number of pacemaker-, ICD- and CRT-
implants and can thus become an additional exposure for resident cardiologists and 
hospitals.  
Furthermore, high individual costs arise for patient transport. Remote monitoring can act as 
a contribution to individualization of follow-up scheduling. This is of particular importance 
in the way that different patient groups require different follow-up scenarios.  
One retrospective study of 271 patients with ICD-indication followed for 12 months using 
Home Monitoring by Brugada et al. examined the utility of remote monitoring in forecasting 
the necessity of a previously scheduled routine in-clinic visit. 908 pairs of Home Monitoring 
data and follow-up data were evaluated. The largest fraction of 608 (67%) consisted of true 
negative forecasts, while a total of 141 (16%) of the forecasts turned out to be true positive in 
accordance with retrospective follow-up view. There was a 14% false negative rate. 
Problems would not have been detected without routine follow-up visits. This particularly 
effects is caused by an increase in ventricular or atrial pacing threshold, discovery of lead 
dislodgement, ventricular episodes, misinterpretation of atrial fibrillation. However, the 
incidence of false negative forecasts decreased over time. A patient management with 
additional sources of information (first follow-up, lead problems, hospitalization etc.) could 
decrease the number of misinterpretations and, therefore, the numbers of follow-ups (P. 
Burgada, 2006). 
Despite these positive results, there are still some controversial issues concerning 
particularly the efficiency of device-based remote monitoring in reducing the number of 
follow-ups. Heidbüchel et al. estimated that remote monitoring could potentially lead to a 
decreased frequency of follow-up, if combined with clinical follow-up by the local general 
practitioner (H. Heidbüchel et al., 2008). In contrast, Al-Khatib et al., who assigned 151 
patients with an ICD to remote monitoring versus quarterly interrogations in clinic, could 
found no significant differences in cardiac-related resource utilization at 1 year (S. M. Al-
Khatib et al., 2010). 
Yet, currently available remote monitoring systems can neither substitute an emergency 
service nor can they replace entirely direct contact.  Device-based remote monitoring is 
recommended for patients with stable device-function who have no need of reprogramming 
(B.L. Wilkoff et al., 2008). 
The potential cost/ benefit of remote monitoring for patients with cardiac devices (ICDs, 
CRTs or pacemakers) is another important aspect which has to be taken into account. A 
study by Fauchier et al. showed that remote monitoring of ICDs diminished the costs of 
follow-up. Particularly, they calculated that remote monitoring reduced the overall cost of 
ICD follow-up when the distance between home and the device clinic was >100 km (L. 
Fauchier et al., 2005). A trial of remote monitoring by Raatikainen et al. from Finland 
demonstrated that compared with the in-office visits, remote ICD monitoring required less 
time from both patient and physician to complete the follow-up. Substitution of two routine 
in-office visits during the study by remote monitoring reduced the overall cost of routine 
ICD follow-up by 41% per patient (M.J. P. Raatikainen et al., 2008).  Furthermore, it could be 
demonstrated in a study from France that remote monitoring decreases the duration of post-
operative hospitalization after implantation of pacing systems or replacement of pulse 
generators (F. Halimi et al., 2008).  
The issue of patient and physician acceptance of remote monitoring still remains. This 
specifically relates to the concern that direct patient-physician-communication may get lost. 
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An Italian study with 119 patients revealed a high level of acceptance and satisfaction after 
1-year remote control (R. P. Ricci et al., 2010).  
However, despite these promising data and possibilities, device-based remote monitoring of 
antibradycardia pacemaker patients has failed to diffuse so far. There are various reasons for 
that: Different remote monitoring systems are not backward compatible and, thus, not able 
to monitor old generation devices. Secondly, routine follow-ups of patients with implanted 
pacemakers do not impose additional burden on the clinical workload. Furthermore, 
antibradycardia pacemakers are primarily inserted in elderly patients; this might create a 
treshold to apply remote monitoring, despite the fact that experience had shown that the 
technology is manageable by elderly patients. The situation is different for patients with 
ICDs and CRTs; due to its various possibilities device-based remote monitoring will grow in 
importance and, moreover, the population consists of heart failure patients.  
However, there are still barriers for wider adoption. Among physicians, significant barriers 
may be technical problems (e.g. missing internet access, different systems), suspected 
additional expenditure of time and missing refund of expenses. The other barrier is the 
flood of data produced by remote monitoring. In a study by Lazarus 3,004,763 transmissions 
were made by 11,624 recipients of pacemakers, defibrillators and combined ICD-cardiac 
resynchronization therapy (CRT-D) systems. On average, 47.6% of the patients were event-
free (A. Lazarus, 2007). Theuns et al. who examined the impact of remote monitoring on 
clinical workload showed that despite the large number of data transmissions, remote 
monitoring imposed a minimal additional burden on the clinical workload. The median 
number of clinical events/ patient/ month was 0.023 (D.A.J. Theuns et al., 2009).  In order to 
guarantee an efficient analysis and selection of relevant data, specially trained nurses are 
deployed. These pacing expert nurses consult the website and submit critical cases to 
physician (R. P. Ricci et al., 2008).   
Last but not least, the acceptance of device-based remote monitoring in future will depend   
on the development of standards and clinical guidelines. Remote monitoring must prove to 
be of great value in optimizing patient care and increasing efficiency of the health system. 
5. Conclusion and perspective 
Device-based remote monitoring has been increasingly established for many years. This 
system enables data transfer from pacemakers, ICDs and CRTs to the physician. Despite 
technical differences between the providers, the remote monitoring systems consist of 
unified components. The patient monitor connects to the device and transfers the data via 
landline or mobile phone to the providers´ server. There, data are anonymously decoded, 
analysed, and uploaded to a secure internet platform. The patient's physicians have access 
to this platform through identity codes and personal passwords and can also be informed of 
critical events via e-mail, sms or fax.  
Meanwhile, most manufacturers (BIOTRONIK, Medtronic, St. Jude Medical, Boston 
Scientific) have provided their own device-based remote monitoring systems, all of which 
are already used in clinical practice. Safety and stability of data transmission was proven in 
clinical trails. Modern remote monitoring systems are taking several aspects of patient 
monitoring into account; they have developed from pure device monitoring to complex 
patient management systems integrating device-, arrhythmia-, heart failure-, and patient 
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centered-management resulting in comprehensive monitoring with the option of early 
interventions. Modern information processing technologies allow the integration of 
collected data into an electronic health record (EHR) providing, therefore, holistic aftercare 
services and patient monitoring. In the future, fast mobile communication technologies for 
data transfer and internet platforms will be the most important tools. Device-based remote 
monitoring will become standard in monitoring of patients being implanted with complex 
cardiac devices (ICDs, CRTs) which is in accordance to the current guidelines. The next step 
is the transition from monitoring management to therapeutic management. This would be of 
particular benefit for CHF patients. However, although proven to be technically 
manageable, the implementation of these possibilities essentially depends on the acceptance 
on the part of patients, physicians and health insurances. Problems such as data security, 
data storage, cost reimbursement of telemedical solutions should be resolved in this context.  
Further clinical studies are needed to prove the benefits of device-based remote monitoring 
such as patient safety, individual patient´ s follow-up settings and cost/ benefit.  
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